Biogen director gets stock grant and RSU vesting

BIOGEN INC. director Menelas N. Pangalos reported routine equity compensation activity.

Rhea-AI Filing Summary

BIOGEN INC. director Menelas N. Pangalos reported routine equity compensation activity. He received a grant or award of 1,505 shares of Common Stock at a stated price of $0.00 per share, reflecting stock-based director compensation rather than an open-market purchase.

On the same date, he exercised 2,370 Restricted Stock Units into 2,370 shares of Common Stock, fully settling that RSU award. Following these transactions, his direct holdings of Biogen common stock increased to 3,875 shares. Footnotes state that the restricted stock units vest upon the earlier of the next annual meeting or the first anniversary of their respective grant dates.

Insights

Equity compensation analyst

Biogen director receives routine stock grant and RSU vesting, no open-market trades.

Director Menelas N. Pangalos was granted 1,505 Biogen common shares as equity compensation and saw 2,370 Restricted Stock Units convert into common stock. Both transactions are coded as an award and an exercise, not market purchases or sales.

The filing shows his direct common stock position rising to 3,875 shares, with the RSU lot of 2,370 units fully settled and no remaining derivative positions listed. Footnotes clarify that RSUs vest based on the earlier of the next annual meeting or the first anniversary of the grant date.

Insider Trade Summary

2,370 shares exercised/converted

Exercise 3 txns

Insider Pangalos Menelas N

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	2,370	$0.00	$0.00
Exercise	Common Stock	2,370	$0.00	$0.00
Grant/Award	Common Stock	1,505	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 3,875 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.
2. F2. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 17, 2025.

Key Figures

Equity grant: 1,505 shares of Common Stock RSUs exercised: 2,370 Restricted Stock Units Shares after transactions: 3,875 shares of Common Stock +2 more

5 metrics

Equity grant 1,505 shares of Common Stock Award to director on June 9, 2026

RSUs exercised 2,370 Restricted Stock Units Converted into Common Stock on June 9, 2026

Shares after transactions 3,875 shares of Common Stock Direct holdings following reported Form 4 transactions

Exercise/Conversion price $0.00 per share Stated price for RSU conversion and share grant

RSU expiration date June 17, 2026 Expiration date for the 2,370-unit RSU award

Key Terms

Restricted Stock Unit, Exercise or conversion of derivative security, Grant, award, or other acquisition

3 terms

Restricted Stock Unit financial

"security_title: "Restricted Stock Unit" with 2,370.0000 units exercised"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biogen (BIIB) director Menelas Pangalos acquire in this Form 4 filing?

Director Menelas N. Pangalos received an equity grant of 1,505 shares of Biogen Common Stock and had 2,370 Restricted Stock Units convert into common shares. These are compensation-related awards and exercises, not open-market stock purchases or sales.

How many Biogen (BIIB) shares does Menelas Pangalos hold after these transactions?

After the reported transactions, Menelas N. Pangalos directly holds 3,875 shares of Biogen Common Stock. This figure reflects the newly granted 1,505 shares plus shares issued upon conversion of 2,370 Restricted Stock Units as disclosed in the Form 4.

Were there any open-market buys or sells in the Biogen (BIIB) Form 4 for Menelas Pangalos?

No open-market buys or sells are reported. The Form 4 shows a grant of 1,505 shares coded as an award and an exercise of 2,370 Restricted Stock Units into common stock. Both are compensation-related transactions, not market trading activity.

How many Biogen (BIIB) Restricted Stock Units did Menelas Pangalos exercise?

Menelas N. Pangalos exercised 2,370 Restricted Stock Units, which converted into 2,370 shares of Biogen Common Stock. After this exercise, the RSU position related to this lot shows 0 units remaining, indicating the award was fully settled.

What do the vesting terms for Biogen (BIIB) Restricted Stock Units indicate in this filing?

The footnotes state that Biogen Restricted Stock Units vest on the earlier of the company’s next annual meeting or the anniversary of the grant date. These timing conditions explain when RSUs convert into common stock, as seen with the 2,370-unit exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pangalos Menelas N

(Last) (First) (Middle)

C/O BIOGEN INC. 225 BINNEY

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		M		2,370	A	$0	2,370	D
Common Stock	06/09/2026		A		1,505(1)	A	$0	3,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	06/09/2026		M			2,370	(2)	06/17/2026	Common Stock	2,370	$0	0	D

Explanation of Responses:

1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

2. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 17, 2025.

	/s/ Wendell Taylor, attorney-in-fact for Dr. Pangalos	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)